In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation

Blood

Volumn 90, Issue 11, 1997, Pages 4297-4306

  Dorfman, David M ^a   Schultze, Joachim L ^a,b   Shahsafaei, Aliakbar ^a   Michalak, Sabine ^a   Gribben, John G ^a   Freeman, Gordon J ^a   Pinkus, Geraldine S ^a   Nadler, Lee M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; ARTICLE; CLONAL ANERGY; GENE EXPRESSION; GERMINAL CENTER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030701589     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.11.4297     Document Type: Article

References (71)

1. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261, 1994
2. Croft M, Bradley LM, Swain SL: Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 152:2675, 1994
3. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 12:991, 1994
4. Lassila O, Vainio O, Matzinger P: Can B cells turn on virgin T cells? Nature 334:253, 1988
5. Lenschow DJ, Bluestone JA: T cell co-stimulation and in vivo tolerance. Curr Opin Immunol 5:747, 1993
6. Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM: Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 92:8200, 1995
7. Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM: Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 89:3806, 1997
8. Vyth-Dreese FA, Dellemijn TA, van Oostveen JW, Feltkamp CA, Hekman A: Functional expression of adhesion receptors and costimulatory molecules by fresh and immortalized B-cell non-Hodgkin's lymphoma cells. Blood 85:2802, 1995
9. Shamash J, Davies DC, Salam A, Rohatiner AZ, Young BD, Lister TA: Induction of CD80 expression in low-grade B cell lymphoma - A potential immunotherapeutic target. Leukemia 9:1349, 1995
10. Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, Banchereau J, Nadler LM: In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 83:793, 1994
11. Nozawa Y, Wachi E, Tominaga K, Abe M, Wakasa H: A novel monoclonal antibody (FUN-1) identifies an activation antigen in cells of the B-cell lineage and Reed-Sternberg cells. J Pathol 169:309, 1993
12. Freedman AS, Freeman GJ, Segil JM, Lee G, Whitman WF, Nadler LM: B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 143:2714, 1987
13. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
14. Swanson PE, Wick MR: Commercial avidin-biotin-peroxidase complex kits. Am J Clin Pathol 91:S43, 1989
15. Hsu SM, Raine L, Fanger H: The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 75:816, 1981
16. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577, 1981
17. Vandenberghe P, Delabie J, de Boer M, De Wolf-Peeters C, Ceuppens JL: In situ expression of B7/BB1 on antigen-presenting cells and activated B cells: An immunohistochemical study. Int Immunol 5:317, 1993
18. Vyth-Dreese FA, Dellemijn TA, Majoor D, de Jong D: Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue. Eur J Immunol 25:3023, 1995
19. Clark EA, Ledbetter JA: How B and T cells talk to each other. Nature 367:425, 1994
20. Liu Y-J, Barthelemy C, de Boutellier O, Arpin C, Durand I, Banchereau J: Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-2. Immunity 2:239, 1995
21. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, Vankooten C, Liu YJ, Rousset F, Saeland S: The CD40 antigen and its ligand. Annu Rev Immunol 12:881, 1994
22. Ranheim EA, Kipps TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 177:925, 1993
23. Carbone A, Gloghini A, Gruss H-J, Pinto A: CD40 Ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 147:912, 1995
24. Willems F, Marchant A, Delville JP, Gerard C, Delvaux A, Velu T, de Boer M, Goldman M: Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 24:1007, 1994
25. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM: IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 151:1224, 1993
26. Ozawa H, Aiba S, Nakagawa S, Tagami H: Interferon-gamma and interleukin-10 inhibit antigen presentation by Langerhans cells for T helper type 1 cells by suppressing their CD80 (B7-1) expression. Eur J Immunol 26:648, 1996
27. Morel AS, Quaratino S, Douek DC, Londei M: Split activity of interleukin-10 on antigen capture and antigen presentation by human dendritic cells - Definition of a maturative step. Eur J Immunol 27:26, 1997
28. Jenkins MK, Taylor PS, Norton SD, Urdahl KB: CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 147:2461, 1991
29. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 173:721, 1991
30. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL: CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med 175:353, 1992
31. Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE: B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res 54:5420, 1994
32. Rammensee HG: Maintenance of self tolerance in CD4+ T lymphocytes by antigen presentation on resting B cells - A hypothesis. Bone Marrow Transplant 7:26, 1991 (suppl 1)
33. Hodgkin PD, Basten A: B cell activation, tolerance and antigen-presenting function. Curr Opin Immunol 7:121, 1995
34. Yuschenkoff VN, Sethna MP, Freeman GJ, Parker DC: Coexpression of B7-1 and antigen blocks tolerance induction to antigen presented by resting B cells. J Immunol 157:1987, 1996
35. Buhlmann JE, Foy TM, Aruffo A, Crassi KM, Ledbetter JA, Green WR, Xu JC, Shultz LD, Roopesian D, Flavell RA: In the absence of a CD40 signal, B cells are tolerogenic. Immunity 2:645, 1995
36. Eynon EE, Parker DC: Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 175:131, 1992
37. Kubin M, Kamoun M, Trinchieri G: Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 180:211, 1994
38. Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL: B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 55:4980, 1995
39. Gajewski TF, Renauld JC, Van Pel A, Boon T: Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J Immunol 154:5637, 1995
40. Chen PW, Geer DC, Podack ER, Ksander BR: Tumor cells transfected with B7-1 and interleukin-12 cDNA induce protective immunity. Ann NY Acad Sci 795:325, 1996
41. Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, Rosenberg SA, Restifo NP: IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression. J Immunol 156:3357, 1996
42. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411, 1997
43. Massaia M, Attisano C, Beggiato E, Bianchi A, Pileri A: Correlation between disease activity and T-cell CD3 zeta chain expression in a B-cell lymphoma. Br J Haematol 88:886, 1994
44. Schultze JL, Boussiotis VA, Dorfman D, Cardoso AA, Seamon MJ, Afonso HM, Gribben JG, Nadler LM: Absence of anti-follicular lymphoma (FL) specific T cell mediated immunity is associated with significant reduction of T cell zeta chain and granzyme B expression. Blood 85:272a, 1995 (abstr, suppl 1)
45. Wang Q, Stanley J, Kudoh S, Myles J, Kolenko V, Yi T, Tubbs RB, R, Finke J: T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J Immunol 155:1382, 1995
46. Benjamin D, Park CD, Sharma V: Human B cell interleukin 10. Leuk Lymphoma 12:205, 1994
47. Masood R, Zhang Y, Bond MW, Scadden DT, Moudgil T, Law RE, Kaplan MH, Jung B, Espina BM, Lunardi-Iskandar Y: Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 85:3423, 1995
48. Stewart JP, Behm FG, Arrand JR, Rooney CM: Differential expression of viral and human interleukin-10 (IL-10) by primary B cell tumors and B cell lines. Virology 200:724, 1994
49. Benjamin D, Knobloch TJ, Dayton MA: Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 80:1289, 1992
50. Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J, Favrot MC: Serum interleukin-10 in non-Hodgkin's lymphoma: A prognostic factor. Blood 82:2169, 1993
51. Murase T, Jirtle RL, McDonald GB: Transforming growth factor-beta plasma concentrations in patients with leukemia and lymphoma receiving chemoradiotherapy and marrow transplantation. Blood 83:2383, 1994
52. Schultze JL, Michalak S, Seaman MS, Gribben JG, Nadler LM: CD40 activated follicular lymphoma cells are resistant to and can overcome generalized T cell unresponsiveness induced by IL-10 and TGFbeta1. Blood 86:636a. 1996 (abstr, suppl 1)
53. Krolick KA, Isakson PC, Uhr JW, Vitetta ES: BCL1, a murine model for chronic lymphocytic leukemia: Use of the surface immunoglobulin idiotype for the detection and treatment of tumor. Immunol Rev 48:81, 1979
54. Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy SL, Levy R: Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 139:2825, 1987
55. Dunn PL, Johnson CA, Styles JM, Pease SS, Dean CJ: Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge. Immunology 60:181, 1987
56. Eichmann K, Emmrich F, Kaufmann SH: Idiotypic vaccinations: Consideration towards a practical application. Crit Rev Immunol 7:193, 1987
57. George AJ, Folkard SG, Hamblin TJ, Stevenson FK: Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol 141:2168, 1988
58. Kwak LW, Campbell M, Levy R: Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: Initial studies in a murine model. Cancer Detect Prevent 15:323, 1991
59. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
60. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345:1016, 1995
61. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE: Idiotype DNA vaccines against B-cell lymphoma. Immunol Rev 145:211, 1995
62. Nelson EL, Li X, Hsu FJ, Kwak LW, Levy R, Clayberger C, Krensky AM: Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88:580, 1996
63. Tao MH, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755, 1993
64. Chen TT, Tao MH, Levy R: Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 153:4775, 1994
65. Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M: Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24:605, 1994
66. Flamand V, Sornasse T, Thielemans K, Demanet C, Leo O, Urbain J, Moser M: Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma. Adv Exp Med Biol 329:611, 1993
67. Flamand V, Lespagnard L, Thielemans K, Leo O, Urbain J, Moser M: Enhancement of a spontaneous immune response against a B-cell lymphoma by dendritic cells leads to protection against the tumor. Ann NY Acad Sci 690:382, 1993
68. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996
69. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093, 1992
70. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065, 1992
71. Chen L, Linsley PS, Hellstrom KE: Costimulation of T cells for tumor immunity. Immunol Today 14:483, 1993